In:
Current Opinion in Endocrinology, Diabetes & Obesity, Ovid Technologies (Wolters Kluwer Health), Vol. 29, No. 2 ( 2022-04), p. 183-190
Abstract:
To summarize recent developments of long-acting amylin analogues for the treatment of obesity and to outline their mode of action. Recent findings Amylin is a pancreatic hormone acting to control energy homeostasis and body weight. Activity at the calcitonin and amylin receptors in the area postrema seems to – at least partly – be responsible for these effects of amylin. Both preclinical and early-stage clinical studies investigating long-acting amylin receptor analogues demonstrate beneficial effects on body weight in obesity. Cagrilintide, a novel amylin analogue suitable for once-weekly administration, is in phase II clinical development and has shown promising body weight reducing effects alone and in combination with the glucagon-like peptide 1 receptor agonist semaglutide. Summary Long-acting amylin analogues have emerged as a possible pharmacotherapy against obesity, but more studies are needed to support the utility and long-term effects of this strategy in relevant populations.
Type of Medium:
Online Resource
ISSN:
1752-296X
,
1752-2978
DOI:
10.1097/MED.0000000000000716
Language:
English
Publisher:
Ovid Technologies (Wolters Kluwer Health)
Publication Date:
2022
detail.hit.zdb_id:
2273420-X
